Strategies to overcome antileishmanial drugs unresponsiveness

Journal of Tropical Medicine

Volumn 2014, Issue , 2014, Pages

  Sundar, Shyam ^a   Singh, Anup ^a   Singh, Om Prakash ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; MILTEFOSINE; MOLECULAR MARKER; PAROMOMYCIN; SITAMAQUINE; STIBOGLUCONATE SODIUM;

AMASTIGOTE; ARTICLE; CLINICAL PROTOCOL; DORMANCY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG RESPONSE; DRUG TREATMENT FAILURE; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; HUMAN GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LEISHMANIASIS; MIXED INFECTION; PATIENT COMPLIANCE; PATIENT MONITORING; POST KALA AZAR DERMAL LEISHMANIASIS; PRODUCTIVITY; SKIN LEISHMANIASIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84901266793     PISSN: 16879686     EISSN: 16879694     Source Type: Journal    
DOI: 10.1155/2014/646932     Document Type: Article

References (61)

1. World Health Organization, Regional Technical Advisory Group on Kala-Azar Elimination. Report of the First Meeting, Manesar, Haryana, 20-23 December 2004 2005 New Delhi, India Regional Office for South-East Asia
2. Jha T. K., Singh N. K., Jha S. N., Therapeutic use of sodium stibogluconate in kala-azar from some hyperendemic districts of N.Bihar. Journal of the Association of Physicians of India 1992 40 868
3. Laguna F., Videla S., Jiménez-Mejías M. E., Sirera G., Torre-Cisneros J., Ribera E., Prados D., Clotet B., Sust M., López-Vélez R., Alvar J., Viciana P., Navarro T., Kindelán J. M., Azuaje C., Altés J., Arribas J. R., Boix V., Gatell J. M., de Górgolas M., Márquez M., Pulido F., Rubio R., Salas A., Sanz J., Cañavate C., Chicharro C., Cruz I., Morales M. A., Casals S., García C., Sanz A., Puyada A., Tolrà I., Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. Journal of Antimicrobial Chemotherapy 2003 52 3 464 468 2-s2.0-10744227879 10.1093/jac/dkg356 (Pubitemid 37120727)
4. Mishra M., Biswas U. K., Jha D. N., Khan A. B., Amphotericin versus pentamidine in antimony-unresponsive kala-azar. The Lancet 1992 340 8830 1256 1257 2-s2.0-0026466052 10.1016/0140-6736(92)92952-C
5. Thakur C. P., Singh R. K., Hassan S. M., Kumar R., Narain S., Kumar A., Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Transactions of the Royal Society of Tropical Medicine and Hygiene 1999 93 3 319 323 2-s2.0-0032804471 10.1016/S0035-9203(99)90037-8 (Pubitemid 29348832)
6. Berman J. D., U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clinical Infectious Diseases 1999 28 1 49 51 2-s2.0-0032618649 (Pubitemid 29246124)
7. Sundar S., Agrawal N. K., Sinha P. R., Horwith G. S., Murray H. W., Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Annals of Internal Medicine 1997 127 2 133 137 2-s2.0-0030787429 (Pubitemid 27337398)
8. Sundar S., Jha T. K., Thakur C. P., Mishra M., Singh V. P., Buffels R., Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. The American Journal of Tropical Medicine and Hygiene 2002 66 2 143 146 2-s2.0-0036314758 (Pubitemid 34755644)
9. Sundar S., Makharia A., More D. K., Agrawal G., Voss A., Fischer C., Bachmann P., Murray H. W., Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clinical Infectious Diseases 2000 31 4 1110 1113 2-s2.0-0034450717 10.1086/318122 (Pubitemid 32299377)
10. Bryceson A., A policy for leishmaniasis with respect to the prevention and control of drug resistance. Tropical Medicine and International Health 2001 6 11 928 934 2-s2.0-0034772197 10.1046/j.1365-3156.2001.00795.x (Pubitemid 33010880)
11. Sundar S., Singh A., Rai M., Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clinical Infectious Diseases 2012 55 543 550 10.1093/cid/cis474
12. Dorlo T. P., Balasegaram M., Beijnen J. H., de Vries P. J., Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. Journal of Antimicrobial Chemotherapy 2012 67 2576 2597 10.1093/jac/dks275
13. Dorlo T. P., Rijal S., Ostyn B., Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. The Journal of Infectious Diseases 2014 10.1093/infdis/jiu039
14. Jha T. K., Sundar S., Thakur C. P., Felton J. M., Sabin A. J., Horton J., A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. The American Journal of Tropical Medicine and Hygiene 2005 73 6 1005 1011 2-s2.0-29844441606 (Pubitemid 43038244)
15. Wasunna M. K., Rashid J. R., Mbui J., Kirigi G., Kinoti D., Lodenyo H., Felton J. M., Sabin A. J., Horton J., A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. The American Journal of Tropical Medicine and Hygiene 2005 73 5 871 876 2-s2.0-28044436746 (Pubitemid 41688461)
16. Sundar S., Jha T. K., Thakur C. P., Sinha P. K., Bhattacharya S. K., Injectable paromomycin for visceral leishmaniasis in India. New England Journal of Medicine 2007 356 25 2571 2581 2-s2.0-34250717991 10.1056/NEJMoa066536 (Pubitemid 46961002)
17. DNDi Annual Report, http://www.dndi.org/flippable/annualreport2012/
18. El-Safi S., Kheir M. M., Bucheton B., Argiro L., Abel L., Dereure J., Dedet J. P., Dessein A., Genes and environment in susceptibility to visceral leishmaniasis. Comptes Rendus-Biologies 2006 329 11 863 870 2-s2.0-33750179732 10.1016/j.crvi.2006.07.007 (Pubitemid 44597155)
19. Bhattacharyya T., Bowes D. E., El-Safi S., Significantly lower anti-Leishmania IgG responses in Sudanese versus Indian visceral leishmaniasis. PLOS Neglected Tropical Diseases 2014 8 2 e2675 10.1371/journal.pntd.0002675
20. Khalil E. A. G., El Hassan A. M., Zijlstra E. E., Hashim F. A., Ibrahim M. E., Ghalib H. W., Ali M. S., Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond. Annals of Tropical Medicine and Parasitology 1998 92 2 151 158 2-s2.0-0031910120 10.1080/00034989859988 (Pubitemid 28140463)
21. Leslie T., Kaur H., Mohammed N., Kolaczinski K., Ord R. L., Rowland M., Epidemic of Plasmodium falciparum malaria involving substandard antimalarial drugs, Pakistan, 2003. Emerging Infectious Diseases 2009 15 11 1753 1759 2-s2.0-70350453956 10.3201/eid1511.090886
22. Sundar S., Thakur B. B., Tandon A. K., Agrawal N. R., Mishra C. P., Mahapatra T. M., Singh V. P., Clinicoepidemiological study of drug resistance in Indian kala-azar. British Medical Journal 1994 308 6924 307 2-s2.0-23444451878 (Pubitemid 24084143)
23. Sundar S., Murray H. W., Availability of miltefosine for the treatment of kala-azar in India. Bulletin of the World Health Organization 2005 83 5 394 395 2-s2.0-18944370727 (Pubitemid 40704871)
24. WHO Report, Control of the Leishmaniases-Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases 2010 949 WHO Technical Report Series
25. Sundar S., Rai M., Chakravarty J., Agarwal D., Agrawal N., Vaillant M., Olliaro P., Murray H. W., New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin b followed by short-course oral miltefosine. Clinical Infectious Diseases 2008 47 8 1000 1006 2-s2.0-53349151814 10.1086/591972
26. Sundar S., Sinha P. K., Rai M., Verma D. K., Nawin K., Alam S., Chakravarty J., Vaillant M., Verma N., Pandey K., Kumari P., Lal C. S., Arora R., Sharma B., Ellis S., Strub-Wourgaft N., Balasegaram M., Olliaro P., Das P., Modabber F., Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. The Lancet 2011 377 9764 477 486 2-s2.0-79551683357 10.1016/S0140-6736(10)62050-8
27. Haldar A. K., Sen P., Roy S., Use of antimony in the treatment of leishmaniasis: current status and future directions. Molecular Biology International 2011 2011 23 571242 10.4061/2011/571242
28. Vanaerschot M., Decuypere S., Downing T., Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent. Journal of Infectious Diseases 2012 206 752 755 10.1093/infdis/jis424
29. Bhandari V., Kulshrestha A., Deep D. K., Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLOS Neglected Tropical Diseases 2012 6 e1657 10.1371/journal.pntd.0001657
30. Coelho A. C., Boisvert S., Mukherjee A., Leprohon P., Corbeil J., Ouellette M., Multiple mutations in heterogeneous miltefosine-resistant leishmania major population as determined by whole genome sequencing. PLoS Neglected Tropical Diseases 2012 6 2 2-s2.0-84857860666 10.1371/journal.pntd. 0001512 e1512
31. Fernandez O., Diaz-Toro Y., Valderrama L., Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp. Journal of Clinical Microbiology 2012 50 2207 2211
32. Lira R., Sundar S., Makharia A., Kenney R., Gam A., Saraiva E., Sacks D., Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. Journal of Infectious Diseases 1999 180 2 564 567 2-s2.0-0033509735 10.1086/314896 (Pubitemid 30256350)
33. Dube A., Singh N., Sundar S., Singh N., Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitology Research 2005 96 4 216 223 2-s2.0-21644432930 10.1007/s00436-005-1339-1 (Pubitemid 40933669)
34. Rijal S., Yardley V., Chappuis F., Decuypere S., Khanal B., Singh R., Boelaert M., De Doncker S., Croft S., Dujardin J.-C., Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Microbes and Infection 2007 9 4 529 535 2-s2.0-33947373049 10.1016/j.micinf.2007.01.009 (Pubitemid 46442794)
35. Relling M. V., Klein T. E., CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clinical Pharmacology and Therapeutics 2011 89 3 464 467 2-s2.0-79951809825 10.1038/clpt.2010.279
36. Preissner S. C., Hoffmann M. F., Preissner R., Dunkel M., Gewiess A., Preissner S., Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS ONE 2013 8 12 e82562
37. Preissner S., Kroll K., Dunkel M., Senger C., Goldsobel G., Kuzman D., Guenther S., Winnenburg R., Schroeder M., Preissner R., SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Research 2009 38 1 D237 D243 2-s2.0-75549086408 10.1093/nar/gkp970 gkp970
38. Ghosh A., Zhang W. W., Matlashewski G., Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 2001 20 1-2 59 66 2-s2.0-0035850989 10.1016/S0264-410X(01)00322-X (Pubitemid 32905314)
39. Carrillo E., Crusat M., Nieto J., Chicharro C., Thomas M. D. C., Martínez E., Valladares B., Cañavate C., Requena J. M., López M. C., Alvar J., Moreno J., Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Vaccine 2008 26 15 1902 1911 2-s2.0-40849114492 10.1016/j.vaccine.2008.01.042
40. Rafati S., Zahedifard F., Nazgouee F., Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 2006 24 12 2169 2175 2-s2.0-32844459122 10.1016/j.vaccine.2005.11.011 (Pubitemid 43255160)
41. Gurunathan S., Sacks D. L., Brown D. R., Reiner S. L., Charest H., Glaichenhaus N., Seder R. A., Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. Journal of Experimental Medicine 1997 186 7 1137 1147 2-s2.0-0030822043 10.1084/jem.186.7.1137 (Pubitemid 27441157)
42. Stober C. B., Lange U. G., Roberts M. T. M., Alcami A., Blackwell J. M., IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. Journal of Immunology 2005 175 4 2517 2524 2-s2.0-23444440849 (Pubitemid 41113863)
43. Connell N. D., Medina-Acosta E., McMaster W. R., Bloom B. R., Russell D. G., Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proceedings of the National Academy of Sciences of the United States of America 1993 90 24 11473 11477 2-s2.0-0027141144 10.1073/pnas.90.24.11473 (Pubitemid 24008661)
44. Noazin S., Khamesipour A., Moulton L. H., Tanner M., Nasseri K., Modabber F., Sharifi I., Khalil E. A. G., Bernal I. D. V., Antunes C. M. F., Smith P. G., Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis-a meta-analysis. Vaccine 2009 27 35 4747 4753 2-s2.0-67650506229 10.1016/j.vaccine.2009.05.084
45. Singh O. P., Stober C. B., Singh A. K., Blackwell J. M., Sundar S., Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis. PLOS Neglected Tropical Diseases 2012 6 e1874 10.1371/journal.pntd.0001874
46. Kumar R., Goto Y., Gidwani K., Cowgill K. D., Sundar S., Reed S. G., Evaluation of Ex Vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. The American Journal of Tropical Medicine and Hygiene 2010 82 5 808 813 2-s2.0-77952725081 10.4269/ajtmh.2010.09-0341
47. Chakravarty J., Kumar S., Trivedi S., Rai V. K., Singh A., Ashman J. A., Laughlin E. M., Coler R. N., Kahn S. J., Beckmann A. M., Cowgill K. D., Reed S. G., Sundar S., Piazza F. M., A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 2011 29 19 3531 3537 2-s2.0-79955028631 10.1016/j.vaccine.2011.02.096
48. Alvar J., Aparicio P., Aseffa A., The relationship between leishmaniasis and AIDS: the second 10 years. Clinical Microbiology Reviews 2008 21 334 359 10.1128/CMR.00061-07 (Pubitemid 351555511)
49. Thakur C. P., Kumar K., Sinha P. K., Mishra B. N., Pandey A. K., Treatment of post-kalar-azar dermal leishmaniasis with sodium stibogluconate. British Medical Journal 1987 295 6603 886 887 2-s2.0-0023205670 (Pubitemid 17148526)
50. Thakur C. P., Narain S., Kumar N., Hassan S. M., Jha D. K., Kumar A., Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Annals of Tropical Medicine and Parasitology 1997 91 6 611 616 2-s2.0-0030828290 10.1080/00034989760707 (Pubitemid 27434595)
51. Musa A. M., Khalil E. A. G., Mahgoub F. A., Hamad S., Elkadaru A. M. Y., El Hassan A. M., Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Annals of Tropical Medicine and Parasitology 2005 99 6 563 569 2-s2.0-24044546499 10.1179/136485905X514127 (Pubitemid 41215648)
52. Sundar S., Sinha P., Jha T. K., Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. Tropical Medicine & International Health 2012 18 96 100
53. Reyburn H., Ashford R., Mohsen M., Hewitt S., Rowland M., A randomized controlled trial of insecticide-treated bednets and chaddars or top sheets, and residual spraying of interior rooms for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan. Transactions of the Royal Society of Tropical Medicine and Hygiene 2000 94 4 361 366 2-s2.0-0033847909 (Pubitemid 30662338)
54. Ritmeijer K., Davies C., Van Zorge R., Wang S.-J., Schorscher J., Dongu'du S. I., Davidson R. N., Evaluation of a mass distribution programme for fine-mesh impregnated bednets against visceral leishmaniasis in eastern Sudan. Tropical Medicine and International Health 2007 12 3 404 414 2-s2.0-33847140181 10.1111/j.1365-3156.2006.01807.x (Pubitemid 46280637)
55. Picado A., Singh S. P., Rijal S., Sundar S., Ostyn B., Chappuis F., Uranw S., Gidwani K., Khanal B., Rai M., Paudel I. S., Das M. L., Kumar R., Srivastava P., Dujardin J. C., Vanlerberghe V., Andersen E. W., Davies C. R., Boelaert M., Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. British Medical Journal 2010 341 c6760 2-s2.0-78651394675
56. Singh R., Das R. K., Sharma S. K., Resistance of sandflies to DDT in Kala-azar endemic districts of Bihar, India. Bulletin of the World Health Organization 2001 79 8 793 2-s2.0-0034888390 (Pubitemid 32776849)
57. El-On J., Current status and perspectives of the immunotherapy of leishmaniasis. Israel Medical Association Journal 2009 11 10 623 628 2-s2.0-70350630449
58. Mukhopadhyay D., Saha P., Chatterjee M., Targets for immunochemotherapy in leishmaniasis. Expert Review of Anti-Infective Therapy 2012 10 3 261 264 2-s2.0-84858168877 10.1586/eri.12.17
59. Badaro R., Falcoff E., Badaro F. S., Carvalho E. M., Pederal-Sampaio D., Barral A., Carvalho J. S., Barral-Netto M., Brandely M., Silva L., Bina J. C., Teixeira R., Falcoff R., Rocha H., Ho J. L., Johnson W. D. Jr., Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. New England Journal of Medicine 1990 322 1 16 21 2-s2.0-0025139949 (Pubitemid 20023828)
60. Squires K. E., Rosenkaimer F., Sherwood J. A., Forni A. L., Were J. B. O., Murray H. W., Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. The American Journal of Tropical Medicine and Hygiene 1993 48 5 666 669 2-s2.0-0027190733 (Pubitemid 23187196)
61. Sundar S., Murray H. W., Effect of treatment with interferon- γ alone in visceral leishmaniasis. Journal of Infectious Diseases 1995 172 6 1627 1629 2-s2.0-0028844536